Ocular Therapeutix completes Phase 2
- Ocular Therapeutix said its glaucoma implant OTX-TIC, also called PAXTRAVA, has completed a Phase 2 trial in open-angle glaucoma and ocular hypertension patients. - The completed study enrolled 83 patients, compared two OTX-TIC doses against Durysta, and listed actual study completion on January 24, 2025. - Ocular says it is evaluating next steps after earlier six-month data showed 24% to 30% intraocular pressure reductions. (clinicaltrials.gov) (biospace.com)
Glaucoma damages the optic nerve when pressure inside the eye stays too high, and many patients control it with daily prescription drops. Ocular Therapeutix now says its injected drug implant OTX-TIC has completed a Phase 2 trial in open-angle glaucoma and ocular hypertension. (clinicaltrials.gov) (stocktitan.net) OTX-TIC, also called PAXTRAVA, is a tiny hydrogel drug depot placed inside the eye’s front chamber, where it slowly releases travoprost instead of relying on patients to remember drops every day. Ocular describes it as a bioresorbable implant designed for long-term pressure reduction and maintenance. (ocutx.com) (biospace.com) The Phase 2 study was a prospective, randomized, controlled trial that compared two OTX-TIC dose strengths with a single Durysta implant in patients with open-angle glaucoma or ocular hypertension. ClinicalTrials.gov lists 83 actual enrollees, a study start date of March 16, 2022, primary completion on January 24, 2024, and study completion on January 24, 2025. (clinicaltrials.gov) Ocular had already reported six-month topline data from the trial in April 2024. The company said a single 26-microgram PAXTRAVA implant produced statistically significant pressure reductions through six months, with mean intraocular pressure down 24% to 30% and p-values below 0.0001. (biospace.com) The company also said 81.3% of treated eyes did not need additional pressure-lowering therapy through six months. It reported the implant was generally well tolerated, with no observed impact on corneal health and bioresorption that suggested repeat dosing might be possible without implant stacking. (biospace.com) What changed this week is the program’s status. In Ocular’s April 2026 conference update and in prior securities filings, the company described OTX-TIC as having completed Phase 2 rather than still being in Phase 2. (stocktitan.net) (publicnow.com) Ocular has not yet announced a Phase 3 start for OTX-TIC. Its September 30, 2025 quarterly report said the company was still evaluating next steps for the program. (publicnow.com) That leaves OTX-TIC as a secondary program while Ocular’s investor presentations focus more heavily on AXPAXLI, its late-stage retinal disease candidate. But the glaucoma implant remains on the company’s pipeline page as a completed Phase 2 asset aimed at reducing dependence on daily drops. (ocutx.com 1) (ocutx.com 2) For patients, the pitch is simple: replace a daily routine with a doctor-delivered implant that wears away over time. For Ocular, the next real milestone is no longer Phase 2 completion, but whether it advances OTX-TIC into a registrational plan. (ocutx.com) (publicnow.com)
